



Brian Malkin Examines the DEA's Latest Kratom Scheduling Actions in Drug Discovery & Development

Spencer Fane attorney [Brian Malkin](#) authored the article [DEA Targets Synthetic Kratom-Related Products Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 for Temporary Controls in Schedule I](#), recently published by *Drug Discovery & Development*.

In the article, Brian discusses the DEA's latest actions to regulate certain synthetic kratom-related substances and the broader implications for the kratom industry. He explains the agency's rationale for increasing regulatory oversight, outlines ongoing efforts to establish thresholds for related compounds, and highlights areas where regulators are still seeking public input.

"Manufacturers, retailers, and researchers for products containing these kratom-related substances should continue to monitor the DEA's scheduling orders and develop action plans to respond as the deadlines for action have been coming quick and continue to be in flux," Brian wrote.

At the firm, Brian streamlines processes for clients navigating the complex intersection of patent law and food and drug law, leveraging unique public and private sector experience, in-depth creative and strategic analysis, and advanced negotiation tactics to meet and exceed stakeholder expectations.

Read Brian's full article [here](#).